Depression in Myotonic Dystrophy type 1: Clinical and neuronal correlates

Behavioral and Brain Functions

Volumn 6, Issue , 2010, Pages

  Winblad, Stefan ^a,b   Jensen, Christer ^a   Månsson, Jan Eric ^c   Samuelsson, Lena ^a   Lindberg, Christopher ^a,c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; EDUCATIONAL STATUS; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FEMALE; GENETIC ANALYSIS; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; MALE; MYOTONIC DYSTROPHY; MYOTONIC DYSTROPHY TYPE 1; PRIORITY JOURNAL; SCORING SYSTEM; SPINAL MUSCULAR ATROPHY; WHITE MATTER; ADOLESCENT; BRAIN; MIDDLE AGED; MYELINATED NERVE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PREVALENCE; PSYCHOLOGICAL RATING SCALE; RISK FACTOR;

ADOLESCENT; ADULT; BRAIN; DEPRESSIVE DISORDER; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCULAR ATROPHY, SPINAL; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; MYOTONIC DYSTROPHY; NERVE FIBERS, MYELINATED; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; YOUNG ADULT;

EID: 77952298646     PISSN: 17449081     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-9081-6-25     Document Type: Article

References (36)

1. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007, 370:851-58. 10.1016/S0140-6736(07)61415-9, 17826170.
2. Benedetti F, Bernasconi A, Potiggia A. Depression and neurological disorders. Curr Opin Psychiatry 2006, 19:14-18. 10.1097/01.yco.0000194147.88647.7f, 16612173.
3. Kalkman JS, Schillings ML, Zwarts MJ, van Engelen BGM, Bleijenberg G. Psychiatric disorders appear equally in patients with myotonic dystrophy, facioscapulohumeral dystrophy, and hereditary motor and sensory neuropathy type I. Acta Neurol Scand 2007, 115:265-70. 10.1111/j.1600-0404.2006.00737.x, 17376125.
4. Meola G. Myotonic dystrophies. Curr Opin Neurol 2000, 13:519-25. 10.1097/00019052-200010000-00003, 11073357.
5. Cooper TA. Chemical reversal of the RNA gain of function in myotonic dystrophy. PNAS 2009, 44:18433-34.
6. Wheeler TM, Sobczak K, Lueck JD, Osborne RJ, Lin X, Dirksen RT, Thornton CA. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009, 325:336-39. 10.1126/science.1173110, 19608921.
7. Meola G, Sansone V. Cerebral involvement in myotonic dystrophies. Muscle Nerve 2007, 36:294-306. 10.1002/mus.20800, 17486579.
8. Winblad S, Månsson JE, Blennow K, Jensen C, Samuelsson L, Lindberg C. Cerebrospinal fluid tau and amyloid beta42 protein in patients with myotonic dystrophy type 1. Eur J Neurol 2008, 15:947-52. 10.1111/j.1468-1331.2008.02217.x, 18637827.
9. Winblad S, Lindberg C, Hansen S. Cognitive deficits and CTG repeat expansion size in classical myotonic dystrophy (DM1). Behav Brain Funct 2006, 2:16. 10.1186/1744-9081-2-16, 1475858, 16696870.
10. Winblad S, Lindberg C, Hansen S. Temperament and character in patients with classical myotonic dystrophy type 1 (DM-1). Neuromuscul Disord 2005, 15:287-92. 10.1016/j.nmd.2004.12.003, 15792867.
11. Antonini G, Soscia F, Giubilei F, De Carolis A, Gragnani F, Morinio S, et al. Health-related quality of life in myotonic dystrophy type 1 and its relationship with cognitive and emotional functioning. J Rehabil Med 2006, 38:181-85. 10.1080/16501970500477967, 16702085.
12. Brumback RA, Carlson KM. The depression of myotonic dystrophy: response to imipramine. J Neurol Neurosurg Psychiatry 1983, 46:587-8. 10.1136/jnnp.46.6.587, 1027462, 6875601.
13. Bungener C, Jouvent R, Delaporte C. Psychopathological and emotional deficits in myotonic dystrophy. J Neurol Neurosurg Psychiatry 1998, 65:353-56. 10.1136/jnnp.65.3.353, 2170247, 9728948.
14. Meola G, Sansone V, Perani D, Scarone S, Cappa S, Dragoni C, et al. Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). Neuromuscul Disord 2003, 13:813-21. 10.1016/S0960-8966(03)00137-8, 14678804.
15. Duveneck MJ, Portwood MM, Wicks JJ, Lieberman JS. Depression in myotonic muscular dystrophy. Arch Phys Med Rehabil 1986, 67:875-77.
16. Nordenskiöld U, Grimby G. Grip force in patients with rheumatoid arthtritis and fibromyalgia and in healthy subjects. A study with the Grippit instrument. Scand J Rheumatol 1993, 22:14-19. 10.3109/03009749309095105, 8434241.
17. Mathieu J, Boivin H, Meunier D, Gaudreault M, Begin P. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurol 2001, 56:336-40.
18. Brooke MH. A clinician's view of neuromuscular diseases. 1986, Baltimore: Williams and Wilkinson, 2.
19. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh JK. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-71.
20. Beck AT, Steer RA. Beck Depression Inventory. Manual-Swedish version. Psykologiförlaget. Fagernes, Norge 1996,
21. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman R. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. Am J Roentgenol 1987, 149:351-56.
22. Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993, 114:7-12. 10.1016/0022-510X(93)90041-V, 8433101.
23. Di Costanzo A, Di Salle F, Santoro L, Tessitore A, Bonavita A, Tedeschi G. Pattern and significance of white matter abnormalities in myotonic dystrophy type 1: an MRI study. J Neurol 2002, 249:1175-1182. 10.1007/s00415-002-0796-z, 12242535.
24. Sjögren M, Vanderstichele H, Ågren H, Zachrisson O, Edsbagge M, Wickelso C. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001, 47:1776-81.
25. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Perre B, Sjögren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000, 285:49-52. 10.1016/S0304-3940(00)01036-3, 10788705.
26. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3'end of a transcript encoding a protein kinase family member. Cell 1992, 68:799-808. 10.1016/0092-8674(92)90154-5, 1310900.
27. Gelder MG, Lopéz J, Andreasen NC, . (ed) New Oxford textbook of psychiatry. 2000, New York: Oxford University Press, (ed).
28. Diagnostic and statistical manual of mental disorders DSM-IV-TR. 2000, New York: American Psychiatric Publishing, Fourth.
29. Tickle-Degnen L, Lyons KD. Practitioners' impressions of patients with Parkinson's disease: the social ecology of the expressive mask. Soc Sci Med 2004, 58:603-14. 10.1016/S0277-9536(03)00213-2, 14652056.
30. Brown R, Jahanshahi M. Depression in Parkinson's disease: a psychosocial viewpoint. Adv Neurol 1995, 65:61-84.
31. Koenigs M, Huey ED, Raymont V, Cheon B, Solomon J, Wassermann EM, et al. Focal brain damage protects against post-traumatic stress disorder in combat veterans. Nat Neurosci 2008, 11:232-37. 10.1038/nn2032, 2693133, 18157125.
32. Orfei MD, Robinson RG, Bria P, Caltagironi C, Spalletta G. Unawareness of illness in neuropsychiatric disorders: phenomenological certainty versus etiopathogenic vagueness. Neuroscientist 2008, 14:203-22. 10.1177/1073858407309995, 18057389.
33. Orlikowski D, Chevret S, Quera-Salva MA, Laforêt P, Lofaso F, Verschueren A, et al. Modafinil for the treatment of hypersomnia associated with myotonic muscular dystrophy in adults: a multicenter, prospective, randomized, double-blind, placebo-controlled, 4-week trial. Clin Ther 2009, 8:1765-73.
34. Kornblum C, Reul J, Kress W, Grothe C, Amanatidis N, Klockgether T, et al. Cranial magnetic resonance imaging in genetically proven myotonic dystrophy type 1 and 2. J Neurol 2004, 6:710-14.
35. DeRubeis JR, Siegle GJ, Hollon SD. Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nat Rev Neurosci 2008, 9:788-96. 10.1038/nrn2345, 2748674, 18784657.
36. Clark L, Chamberlain SR, Sahakian BJ. Neurocognitive mechanisms in depression: implications for treatment. Ann Rev Neurosci 2009, 32:57-74. 10.1146/annurev.neuro.31.060407.125618, 19400725.